Indoco Remedies share news, announcements and annual reports
NSE: INDOCOBSE: 532612Pharmaceuticals & BiotechnologySmall Cap
Indoco Remedies Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 2005
Last close ₹215.64up ₹7.34 (3.52%)BSE ₹215.85
Share price at the NSE close on 2 Nov 2026. Previous close ₹208.30.
2 Nov: open ₹208.80, high ₹217.49, low ₹208.80
52-week range of traded prices to 2 Nov 2026
₹162.19Low, 30 Mar 2026₹288.00High, 6 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,990 Cr1,173rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 62.32
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹132 crore of one-off items, the largest of them in the quarter to Jun 2026.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.95
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.09%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 3.2%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹132 crore of one-off items, the largest of them in the quarter to Jun 2026.
- −10.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 1.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.96
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 76,52541.2% delivered
Indoco Remedies orders, deals and press releases
85 filed, newest first. Page 2 of 2.
Mar 2022
Aug 2021
Mar 2021
Dec 2020
Sep 2020
Aug 2020
May 2020
Dec 2019
Nov 2019
Oct 2019
Sep 2019
Aug 2019
Jul 2019
Jun 2019
May 2019
Apr 2019
Jan 2019
Nov 2018
Jan 2018
Nov 2017
7 Nov · Business
May 2017
26 May · Business
Sep 2016
21 Sep · Business
Apr 2015
Mar 2010
31 Mar · Business
Company has signed an agreement with Aspen Pharmacare, South Africa for supply of ophthalmic products. Under the agreement, Indoco will licence out the technology and supply the products. Aspen will market the products in emerging markets. It is expected that the arrangement would boost sale proceeds of the Company.
Feb 2008
25 Feb · Business
At the meeting of the Board of Directors of the Company held on February 23, 2008 the following have been approved by the Board: (1) Change of Company's financial year ending from June 30th to March 31st. Consequently, the financial year of the Company for 2007-08 will be for a 9 months' period from July 01, 2007 to March 31, 2008. (2) A Scheme of Amalgamation for a proposal to amalgamate Company's 100% subsidiary, Shree Herbal Technologies Ltd., with the Company.
Jan 2007
24 Jan · Business
January 24,2007 that: "At the meeting of Board of Directors of the Company held today, the following were approved: a) The unaudited financial results of the Company for the quarter ended 31.12.2006 were approved and taken on record by the Board of Directors. b) The amalgamation of the 100% subsidiary of the Company, viz. La Nova Chem (India) Pvt. Ltd., with the Company was approved. The Board also approved the Scheme of Amalgamation for that purpose. c) The acquisition of the pharmaceutical business of SPA Pharmaceuticals Pvt. Ltd., by legal demerger process, was approved. The Board also approved the scheme of amalgamation for that purpose. The Board approved an exchange ratio of 3 equity shares of Indoco Remedies Limited for every 4 equity shares of SPA Pharmaceuticals Pvt. Ltd., for the purpose of the said scheme".